




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 487/04, A61K 31/505, 31/415 // (C07D 487/04, 239:00, 231:00)</p>	A1	<p>(11) International Publication Number: WO 98/46606</p> <p>(43) International Publication Date: 22 October 1998 (22.10.98)</p>		
<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/SE98/00640</p> <p>(22) International Filing Date: 7 April 1998 (07.04.98)</p> <p>(30) Priority Data: 9701398-1 15 April 1997 (15.04.97) SE</p> <p>(71) Applicant (for all designated States except US): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts WD4 8DH (GB).</p> <p>(71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CHESHIRE, David [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). COOPER, Martin [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). DONALD, David [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). THORNE, Philip [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB).</p> <p>(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/SE98/00640</p> <p>(22) International Filing Date: 7 April 1998 (07.04.98)</p> <p>(30) Priority Data: 9701398-1 15 April 1997 (15.04.97) SE</p> <p>(71) Applicant (for all designated States except US): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts WD4 8DH (GB).</p> <p>(71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CHESHIRE, David [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). COOPER, Martin [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). DONALD, David [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). THORNE, Philip [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB).</p> <p>(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(21) International Application Number: PCT/SE98/00640</p> <p>(22) International Filing Date: 7 April 1998 (07.04.98)</p> <p>(30) Priority Data: 9701398-1 15 April 1997 (15.04.97) SE</p> <p>(71) Applicant (for all designated States except US): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts WD4 8DH (GB).</p> <p>(71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CHESHIRE, David [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). COOPER, Martin [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). DONALD, David [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). THORNE, Philip [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB).</p> <p>(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>			
<p>(54) Title: NOVEL COMPOUNDS</p> <p>(57) Abstract</p> <p>The present invention relates to pharmaceutically useful pyrazolo[3,4-<i>d</i>]pyrimidinedione compounds of formula (I), processes for their production, pharmaceutical compositions containing them and their use for the treatment of various diseases.</p>				
				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL COMPOUNDS

The present invention relates to pharmaceutically useful pyrazolo[3,4-*d*]pyrimidinedione compounds, processes for their production, pharmaceutical compositions containing them and their use for the treatment of various diseases.

T-cells play an important role in the immune response, however in autoimmune disease T-cells are activated against particular tissues, e.g. causing the inflammation associated with rheumatoid arthritis. Interleukin-2 (IL-2) is an essential autocrine growth factor for T-cells and hence inhibition of IL-2 transcription is beneficial in the modulation of autoimmune disease. Formation of a transcriptional complex of the protein nuclear factor of activated T-cells-1 (NFAT-1) on the IL-2 promoter is essential for IL-2 transcription. NFAT-1 mediated transcription has therefore been proposed as appropriate molecular target for immunomodulation, Y. Baine *et al.*, *J. Immunol.*, 1995, **154**, 3667–3677. W. F. Michne *et al.*, in *J. Med. Chem.* (1995) **38**, 2557–2569 disclose a number of quinazoline-2,4-diones and pyrrolo[3,4-*d*]pyrimidine-2,4-diones which inhibit transcription regulated by the DNA region bound by the NFAT-1 protein.

According to the invention there is provided a compound of formula (I):



(I)

in which:

R^1 is C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} cycloalkyl;

R^2 is C_{1-4} alkyl or C_{3-6} alkenyl;

R^3 is 1- or 2-indanyl, 1- or 2-(1,2,3,4-tetrahydronaphthalenyl), 9-fluorenyl, acenaphthyl or
5 $CHR^4(CH_2)_nAr$ where n is 0 or 1, R^4 is hydrogen or C_{1-6} alkyl and Ar is quinolinyl,
naphthalenyl, benzodioxolinyl optionally substituted by one or more halogen atoms, or
phenyl optionally substituted by one or more substituent groups selected from halogen,
 C_{1-6} alkyl, C_{1-6} alkoxy and phenylsulfonylmethyl;

W is H, CH_2OH , CO_2H , CO_2C_{1-6} alkyl, $CH_2NR^5R^6$, $CONR^5R^6$, where R^5 and R^6 are
10 independently hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are
attached form a 3- to 8-membered heterocyclic ring optionally further containing an oxygen
atom or a group NR^7 where R^7 is hydrogen or C_{1-6} alkyl, or W is pyridyl or phenyl, each of
which may be optionally substituted by one or more substituent groups selected from
halogen, hydroxyl, C_{1-6} alkyl and C_{1-6} alkoxy;

15 X is a bond or C_{1-5} alkylene;

Y is $S(O)_p$, $C\equiv C$, $CH=CH$, CH_2CH_2 or $CH_2CH=CH$; and

p is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof, provided that:

- X is not a bond when W is H, CH_2OH , CO_2H , CO_2C_{1-6} alkyl, $CH_2NR^5R^6$ or $CONR^5R^6$
20 and Y is sulfur.

Alkyl and alkenyl groups whether alone or as part of another group, may be linear or
branched. As defined herein alkenyl groups are those where the double bond is not
adjacent to a heteroatom.

25

Suitably R^1 is C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} cycloalkyl. Preferably R^1 is a C_{1-4} alkyl or
 C_{3-4} alkenyl group such as methyl, ethyl, propyl, butyl, 2-methyl-1-propyl, propenyl, butenyl
or 2-methyl-2-propenyl.

Suitably R^2 is C_{1-4} alkyl (e.g. methyl, ethyl, propyl, butyl or 2-methyl-1-propyl) or C_{3-6} alkenyl (e.g. propenyl, butenyl, pentenyl, hexenyl or 2-methyl-2-propenyl). Preferably R^2 is C_{1-4} alkyl, most preferably methyl.

5 Suitably R^3 is 1- or 2-indanyl, 1- or 2-(1,2,3,4-tetrahydronaphthalenyl), 9-fluorenyl, acenaphthyl or $CHR^4(CH_2)_nAr$ where n is 0 or 1, R^4 is hydrogen or C_{1-6} alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) and Ar is quinolinyl, naphthalenyl, benzodioxolinyl optionally substituted by one or more, e.g. one, two or three, halogen atoms (e.g. fluorine, chlorine or bromine), or phenyl optionally substituted by one or more, e.g. one to four,
10 preferably one or two, substituent groups selected from halogen (e.g. fluorine, chlorine or bromine), C_{1-6} alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl), C_{1-6} alkoxy (e.g. methoxy, ethoxy, propoxy or butoxy) and phenylsulfonylmethyl.

Preferably R^3 is $CHR^4(CH_2)_nAr$ where n is 0, R^4 is hydrogen and Ar is quinolinyl,
15 naphthalenyl, benzodioxolinyl substituted by one or more halogen atoms, or phenyl substituted by one or more substituent groups selected from halogen atoms and phenylsulfonylmethyl.

Suitably W is H, CH_2OH , CO_2H , CO_2C_{1-6} alkyl, preferably CO_2C_{1-4} alkyl (e.g. CO_2CH_3 ,
20 $CO_2C_2H_5$, $CO_2C_3H_7$ or $CO_2C_4H_9$), $CH_2NR^5R^6$, $CONR^5R^6$, where R^5 and R^6 are independently hydrogen or C_{1-6} alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl), or together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocyclic ring optionally further containing an oxygen atom or a group NR^7 where R^7 is hydrogen or C_{1-6} alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl), or W is pyridyl or
25 phenyl, each of which may be optionally substituted by one or more, e.g. one, two or three, substituent groups selected from halogen (e.g. fluorine, chlorine or bromine), hydroxyl, C_{1-6} alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) and C_{1-6} alkoxy (e.g. methoxy, ethoxy, propoxy or butoxy).

Examples of groups where R⁵ and R⁶ form a 3- to 8-membered heterocyclic ring include piperidine, morpholine and piperazine rings.

Preferably W is H, CH₂OH, CO₂H, CO₂C₁₋₆alkyl or pyridyl.

5

Suitably X is a bond or C₁₋₅alkylene, preferably C₁₋₃alkylene.

Suitably Y is S(O)_p where p is 0, 1 or 2, C≡C, CH=CH, CH₂CH₂ or CH₂CH=CH.

Preferably Y is sulfur or CH₂CH₂.

10

A preferred subset of compounds of formula (I) is one in which R¹ is C₁₋₄alkyl or C₃₋₄alkenyl; R² is C₁₋₄alkyl; R³ is CHR⁴(CH₂)_nAr where n is 0 or 1, R⁴ is hydrogen or C₁₋₆alkyl and Ar is quinoliny, naphthalenyl, benzodioxoliny optionally substituted by one or more halogen atoms, or phenyl optionally substituted by one or more substituent groups
15 selected from halogen, C₁₋₆alkyl, C₁₋₆alkoxy and phenylsulfonylmethyl; W is H, CH₂OH, CO₂H, CO₂C₁₋₆alkyl or pyridyl; X is a bond or C₁₋₃alkylene; and Y is sulfur or CH₂CH₂, provided that:

- X is not a bond when W is H, CH₂OH, CO₂H or CO₂C₁₋₆alkyl and Y is sulfur.

20 An especially preferred subset of compounds of formula (I) is one in which R¹ is C₄alkyl or C₄alkenyl; R² is methyl; R³ is CHR⁴(CH₂)_nAr where n is 0, R⁴ is hydrogen and Ar is quinoliny, naphthalenyl, benzodioxoliny optionally substituted by one or more chlorine atoms, or phenyl optionally substituted by one or more substituent groups selected from halogen and phenylsulfonylmethyl; W is H, CH₂OH, CO₂H, CO₂CH₃ or 2-pyridyl; X is a
25 bond or C₁₋₃alkylene; Y is sulfur or CH₂CH₂, provided that:

- X is not a bond when W is H, CH₂OH, CO₂H or CO₂CH₃ and Y is sulfur.

Particularly preferred compounds of the invention include:

3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione,
30

5-Methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-3-[(2-pyridinyl)thio]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione,

3-[(2-Hydroxyethyl)thio]-5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione,

5 3-(4-Hydroxybutyl)-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione,

5-Methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-propylthio-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione,

10 3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione,

Methyl 4-[(4,5,6,7-tetrahydro-5-methyl-7-{2-methylpropyl}-2-{1-naphthalenylmethyl}-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)thio]butanoic acid,

4-[(4,5,6,7-tetrahydro-5-methyl-7-{2-methylpropyl}-2-{1-naphthalenylmethyl}-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)thio]butanoic acid,

15 3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(2-{phenylsulfonylmethyl}phenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione,

2-({5-Chlorobenzo[1,3]dioxol-6-yl}methyl)-3-[(3-hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione,

20 2-(3-Chloro-2-fluorophenylmethyl)-3-[(3-hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, and

3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(2-quinolinylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione,


and pharmaceutically acceptable salts thereof.

25 Compounds of the invention can form pharmaceutically acceptable salts. The compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example, maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, oxalic, mandelic, tartaric and methanesulfonic acids.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.

According to a further aspect of the invention there is also provided a process for the preparation of a compound of formula (I) which comprises:

(a) reaction of a compound of formula (II):




(II)

in which R^1 , R^2 and R^3 are as defined in formula (I) with a compound of formula (III):




in which L is a leaving group, Y is sulphur, and X and W are as defined in formula (I), or
 (b) when Y is CH_2CH_2 or $CH_2CH=CH$ and R^3 is $CHR^4(CH_2)_nAr$, reaction of a compound of formula (IV):



(IV)

in which $R^{3'}$ is a precursor to the R^3 group $CHR^4(CH_2)_nAr$ and R^1 and R^2 are as defined in formula (I), with a compound of formula (V):


5



in which Y is CH_2CH_2 or $CH_2CH=CH$ and W and X are as defined in formula (I), or



(c) when Y is $C\equiv C$, $CH=CH$ or $CH_2CH=CH$, reacting a compound of formula (VI):

10



(VI)

15 in which L^1 represents a leaving group and R^1 , R^2 and R^3 are as defined in formula (I) with a compound of formula (VII) or (VIII):



20

wherein, in formula (VII), X^a is a bond or C_{1-6} alkylene and W is as defined in formula (I), and wherein, in formula (VIII), W and X are as defined in formula (I), and optionally thereafter:

- converting the compound of formula (I) to a further compound of formula (I), and/or
- forming a pharmaceutically acceptable salt.

The reaction of compounds of formulae (II) and (III) is typically carried out by treating the
5 compound of formula (II) with a suitable base in an inert solvent at reduced temperature.
Suitable bases include lithium diisopropylamide (LDA) in tetrahydrofuran (THF) at or
below -40°C . Preferred leaving groups L include sulfinates, tosyl or tolylsulfinyl.
Alternatively when Y is sulfur, the leaving group itself may be a group of formula Y-X-W
such that the compound of formula (III) is a dimer of formula W-X-S-S-X-W.

10


Compounds of formulae (IV) and (V) are suitably reacted in an inert solvent such as
dimethylformamide (DMF) at elevated temperature, for example at reflux. The group $\text{R}^{3'}$ is
a suitable precursor to R^3 in compounds of formula (I) such that $\text{R}^{3'}$ is an alkylidene
precursor to R^3 .

15

Compounds of formula (I) in which Y represents sulphur can be converted to further
compounds of formula (I) in which Y represents SO or SO_2 by an oxidation reaction using,
for example, as oxidising agent 3-chloroperoxybenzoic acid or potassium
peroxymonosulphate (commercially sold under the trade mark "OXONE").

20


Compounds of formula (II) can be prepared by reaction of a compound of formula (IX):



(IX)

25

in which R^1 and R^2 are as defined in formula (I) with a compound of formula (X):




5 in which L^2 is a leaving group and R^3 is as defined in formula (I).

Reaction of compounds of formula (IX) and (X) is suitably carried out in the presence of a base such as sodium or potassium carbonate in a suitable solvent such as acetone. Suitable leaving groups L^2 include halogen.

10

Compounds of formula (IX) can be prepared by reaction of a compound of formula (XI):



15


(XI)

in which R^1 and R^2 are as defined in formula (I) with dimethylformamide dimethylacetal at elevated temperature, for example at about 90°C or with phosphorus oxychloride (POCl₃) in dimethylformamide (DMF) at about 0°C.

20


Compounds of formula (XI) can be prepared using standard procedures known in the art, for example, by treating the corresponding halide with hydrazine hydrate.

Compounds of formula (IV) can be prepared by reacting a compound of formula (XI) as
25 defined above with a compound of formula (XII):



in which Ar, n and R^4 are as defined in formula (I).

- 5 Reaction of compounds of formula (VI) and (VII) can be carried out in the presence of $\text{Pd}(\text{OAc})_2/\text{P}(\text{O-Tol})_3$ in the presence of a base such as triethylamine in a suitable solvent such as acetonitrile. A mixture of compounds of formula (I) are obtained where X' is X as defined in formula (I) minus one carbon atom:




10

Compounds of formula (VI) and (VIII) can be reacted in the presence of a palladium catalyst with copper iodide in the presence of a base such as triethylamine in a suitable solvent such as acetonitrile. Preferred catalysts include $\text{Pd}(\text{Ph}_3\text{P})_2\text{Cl}_2$.

15

Compounds of formula (VI) can be prepared by reacting a compound of formula (XIII):



20

in which R^1 , R^2 and R^3 are as defined in formula (I), with a base followed by a halogen (e.g. iodine) to become the group L^1 . A compound of formula (XIII) can be treated with an



organic base such as lithium diisopropylamide (LDA) in an inert solvent such as tetrahydrofuran (THF) at reduced temperature, for example at about - 70°C. Iodine is then added and the reaction mixture allowed to warm to ambient temperature.

- 5 Compounds of formula (I) can be converted to further compounds of formula (I) using procedures known in the art. For example the reaction products of process (c) can be hydrogenated to give compounds of formula (I) where X/Y form an alkylene chain. Alternatively compounds of formula (I) where Y is $C\equiv C$ can be hydrogenated using a lindlar catalyst to the corresponding compounds of formula (I) where Y is $C=C$.


10

The group W can also be interconverted, for example when W is CO_2H , compounds of formula (I) can be converted to compounds of formula (I) where W is $CO_2C_{1-6}alkyl$, $CONR^5R^6$ or $CH_2NR^5R^6$. When W is CH_2OH compounds of formula (I) can be converted to compounds of formula (I) where W is $CH_2NR^5R^6$. Suitable procedures for these

- 15 conversions are shown in the scheme below:



20



Compounds of formulae (III), (V), (VII), (VIII), (X) and (XII) are either commercially available, are well known in the literature or may be prepared easily using known techniques.

5 Novel intermediate compounds form a further aspect of the invention.

It will be appreciated by those skilled in the art that in the process steps described above the functional groups of intermediate compounds may need to be protected by protecting groups. The protection of functional groups may take place before any of the process steps
10 hereinbefore described. Protecting groups may be removed following a reaction step or at the end of the reaction process using techniques which are well known to those skilled in the art. The use of protecting groups is fully described in "Protective Groups in Organic Chemistry", edited by J W F McOmie, Plenum Press (1973), and "Protective Groups in Organic Synthesis", 2nd edition, T W Greene & P G M Wuts, Wiley-Interscience (1991).

15

Salts of the compounds of formula (I) may be formed by reacting the free acid, or a salt thereof, or the free base, or a salt thereof, with one or more equivalents of the appropriate base or acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, e.g. ethanol, tetrahydrofuran or diethyl
20 ether, which may be removed *in vacuo*, or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin. The non-toxic physiologically acceptable salts are preferred, although other salts may be useful, e.g. in isolating or purifying the product.

25 The compounds of the present invention are advantageous in that they possess pharmacological activity. They are therefore indicated as pharmaceuticals for use in the (prophylactic) treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS). Examples of these
30 conditions are:

- (1) **(the respiratory tract)** reversible obstructive airways diseases including asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;
- (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- (5) **(other tissues and systemic disease)** multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia purpura;

(6) (**allograft rejection**) acute and chronic following for example transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease.

5 The compounds of the invention are also indicated for use as antimicrobial agents, and thus may be used in the treatment of diseases caused by pathogenic micro-organisms.

Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined for use in therapy.

10

In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

15 In particular, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of an immunosuppressive pharmaceutical composition. The compounds of the invention can also be administered in combination with other immunosuppressants known in the art such as FK506 and Cyclosporin.

20

According to a further aspect of the invention there is provided the use of a compound of formula (I), as hereinbefore defined, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a reversible obstructive airways disease.

25 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disease indicated.

• According to the invention there is further provided a pharmaceutical composition
30 comprising preferably from 0.05 to 99 % w (per cent by weight), e.g. less than 80 % w, and


more preferably from 0.1 to 70 % w, e.g. less than 50 % w, of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined above in combination with a pharmaceutically acceptable diluent or carrier.

- 5 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically-acceptable salt thereof, as hereinbefore defined with a pharmaceutically acceptable diluent or carrier.
- 10 The pharmaceutical composition of the invention may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal
- 15 administration in the form of suppositories or transdermally.

According to a further aspect of the invention, there is provided a method of effecting immunosuppression which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as

20 defined above.

The invention is illustrated by the following examples.

Example 1**3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione****5 (a) 1-Methylbarbituric acid**

Acetic anhydride (17 ml) was added to a solution of malonic acid (10 g) and methylurea (6.25 g) in acetic acid (23 ml) at 65°C. The mixture was heated to 90-95°C for 3 hours then cooled to room temperature. The resulting solution was concentrated under reduced pressure and the residue was redissolved in ethanol (50 ml). Ether (5 ml) was added and the mixture was allowed to stand for 16 hours at room temperature before being chilled for 4 hours at 4°C. The precipitated solid was filtered and washed with ether. The solid was redissolved in warm water (50 ml) and the solution concentrated under reduced pressure until solid started to precipitate. The mixture was cooled to room temperature and the solid that formed was collected and dried *in vacuo* to give the sub-title compound (3.34 g) as a solid.

Melting point: 130-131°C

MS (EI) 142 (M⁺)

¹H NMR (DMSO-d₆) δ 3.05 (3H, s); 3.58 (2H, s); 11.33 (1H, s, br).

20 (b) 6-Chloro-3-methylpyrimidine-2,4[1H,3H]-dione

1-Methylbarbituric acid (10 g) was suspended in phosphorus oxychloride (70 ml). Water (2 ml) was added and the mixture was heated at reflux for 40 minutes. The reaction was allowed to cool and was then concentrated under reduced pressure. The residue was poured onto a mixture of ice and water (200 ml). When the ice had melted, the precipitated

solid was collected, washed with water and dried *in vacuo* at 50°C to give the sub-title compound (6.86 g) as a yellow solid.

MS (EI) 160/162 (M^+)

^1H NMR ($\text{CDCl}_3/\text{DMSO}-d_6$) δ 3.24 (3H, s); 5.74 (1H, s); 12.18 (1H, s, br).

5

(c) 6-Hydrazino-3-methyl-1-(2-methyl-2-propenyl)pyrimidine-2,4[1H,3H]-dione

3-Bromo-2-methylpropene (1.65 ml) and potassium carbonate (4.00 g) were added to a solution of 6-chloro-3-methylpyrimidine-2,4[1H,3H]-dione (2.00 g) in acetone (50 ml). The mixture was heated at reflux for 24 hours and then cooled to room temperature. The solution was filtered and the solid was washed with acetone ($2 \times 25\text{ml}$). The combined filtrate was concentrated under reduced pressure to give a yellow solid (1.25 g). This was redissolved in ethanol (15 ml) and hydrazine hydrate (5 ml) was added. The mixture was heated at reflux for 15 minutes, allowed to cool to room temperature, and then evaporated under reduced pressure. The residue was coevaporated with ethanol ($2 \times 20\text{ml}$) under reduced pressure and was then recrystallised from ethanol to give the subtitle compound (0.75 g).

10

Melting point: 186-188°C

MS (EI) 210 (M^+)

^1H NMR ($\text{DMSO}-d_6$) δ 1.70 (3H, s); 3.10 (3H, s); 4.36 (4H, s, br); 4.44 (1H, s);

20

4.74 (1H, s); 5.12 (1H, s); 7.88 (1H, s, br).

(d) 5-Methyl-7-(2-methyl-2-propenyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6-[5H,7H]-dione

A mixture of 6-hydrazino-3-methyl-1-(2-methyl-2-propenyl)pyrimidine-2,4[1H,3H]-dione (0.575 g) and dimethylformamide dimethylacetal (0.73 ml) was heated at 90°C for 20 minutes. The mixture was allowed to cool and was directly purified by column chromatography over silica eluting with ethyl acetate : hexane (2:1) and then recrystallisation from ethyl acetate/hexane to give the subtitle compound (0.063 g).

25

Melting point: 232-233°C

30

MS (EI) 220 (M^+)

¹H NMR (CDCl₃/DMSO-d₆) δ 1.80 (3H, s); 3.39 (3H, s); 4.60 (2H, s); 4.75 (1H, s); 4.89 (1H, s); 8.04 (1H, s); 13.04 (1H, s, br).

(e) 5-Methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo-[3,4-d]pyrimidine-4,6[5H,7H]-dione

1-(Chloromethyl)naphthalene (0.214 ml) and potassium carbonate (0.60 g) were added to a suspension of 5-methyl-7-(2-methyl-2-propenyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione (0.215 g) in acetone (10 ml). The mixture was stirred at room temperature for 16 hours and then heated at reflux for 2 hours. The mixture was filtered and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography over silica eluting with ethyl acetate : hexane (2:1) followed by recrystallisation from ethyl acetate/hexane to give the subtitle compound (0.062 g).

Melting point: 187-189°C

MS (EI) 360 (M⁺).

¹H NMR (CDCl₃) δ 1.85 (3H, s); 3.35 (3H, s); 4.62 (2H, s); 4.81 (1H, s); 4.95 (1H, s); 5.73 (2H, d); 7.55-7.43 (4H, m); 7.59 (1H, s); 7.85 (1H, d); 7.94-7.92 (2H, m).

(f) 3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione

A solution of lithium diisopropylamide (1.12 mmol) in tetrahydrofuran (6 ml) was added dropwise to a stirred solution of 5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione (0.20 g) and 3-[[dimethyl(1,1-dimethylethyl)silyl]oxy}propyl 4-methylphenylthiosulfonate (J. Med. Chem. 1995, 38, 2557) (0.262 g) in anhydrous tetrahydrofuran (20 ml) at -70 °C.

The solution was stirred for a further 1 hour at -70°C and then allowed to warm to room temperature. Saturated aqueous sodium bicarbonate solution (10 ml) was added and the mixture was extracted with ethyl acetate. The organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residual oil was purified by column chromatography over silica eluting with acetone : hexane (1:5). The product was dissolved in acetonitrile (5 ml) and treated with 40% aqueous hydrofluoric

acid (1 ml). After 5 minutes, the solution was neutralised with aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic extracts were washed with saturated aqueous sodium bicarbonate solution, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica eluting with acetone : hexane (1:5 then 1:3) followed by recrystallisation from diethyl ether/hexane to give the title compound (0.11 g).


Melting point: 138–139°C

MS (FAB) 451 ((M+H)⁺).

¹H NMR (CDCl₃) δ 1.60 (3H, s); 1.75-1.80 (2H, m); 2.66 (1H, s, br); 3.29 (2H, t); 3.42 (3H, s); 3.72-3.78 (2H, m); 4.58 (2H, s); 4.83 (1H, s); 4.93 (1H, s); 5.98 (2H, s); 7.05 (1H, d); 7.42 (1H, t); 7.52-7.60 (2H, m); 7.85 (1H, d); 7.90 (1H, dd); 8.24 (1H, d).

Example 2

5-Methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-3-[(2-pyridinyl)thio]-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione



A solution of lithium diisopropylamide (2.24 mmol) in anhydrous tetrahydrofuran (10 ml) was added dropwise to a stirred solution of 5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione (Example 1(e), 0.20 g) and 2,2'-dipyridyl disulfide (0.246 g) in anhydrous tetrahydrofuran (15 ml) at -78°C. The solution was stirred for a further 0.5 hour at -78°C and then allowed to warm to room temperature. Saturated aqueous sodium bicarbonate solution (10 ml) was added and the mixture was extracted with ethyl acetate. The organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue

was purified by column chromatography over silica eluting with diethyl ether : hexane (1:1 then 2:1) followed by recrystallisation from diethyl ether/hexane to give the title compound (0.08 g).


Melting point: 118–120°C

5 MS (FAB) 470 ((M+H)⁺).

¹H NMR (CDCl₃) δ 1.77 (3H, s); 3.34 (3H, s); 4.58 (2H, s); 4.82 (1H, s); 4.90 (1H, s); 5.96 (2H, s); 7.00-7.04 (2H, m); 7.15 (1H, d); 7.31 (1H, t); 7.38-7.55 (3H, m); 7.75 (1H, d); 7.81-7.84 (1H, m); 8.16-8.21 (1H, m); 8.28-8.32 (1H, m).

10 Example 3

3-[(2-Hydroxyethyl)thio]-5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione



(a) Bis-2-[[dimethyl(1,1-dimethylethyl)silyl]oxy]ethyl disulfide

15 To a stirred solution of 2-hydroxyethyl disulfide (2 g) and imidazole (5.3 g) in dichloromethane (100 ml) was added dimethyl(1,1-dimethylethyl)silyl chloride (5.86 g). The solution was stirred overnight then diluted with diethyl ether, washed sequentially with dilute hydrochloric acid and aqueous sodium bicarbonate solution, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was
20 purified by column chromatography over silica eluting with hexane : diethyl ether (20:1) to give the subtitle compound as a clear oil (3.75 g).

MS (EI) 382 (M-CH₃)⁺.


(b) 3-[(2-Hydroxyethyl)thio]-5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione

A solution of lithium diisopropylamide (3.36 mmol) in anhydrous tetrahydrofuran (25 ml) was added dropwise to a stirred solution of 5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione (Example 1(e), 0.30 g) and bis-2-[[dimethyl(1,1-dimethylethyl)silyl]oxy]ethyl disulfide (0.642 g) in anhydrous tetrahydrofuran (30 ml) at -70°C. The solution was stirred for a further 0.5 hour at -78°C and then allowed to warm to room temperature. Saturated aqueous sodium bicarbonate solution (10 ml) was added and the solution was extracted with ethyl acetate. The organic extracts were dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography over silica eluting with hexane : diethyl ether (2:1). The product was dissolved in acetonitrile (10 ml) and treated with 40% aqueous hydrofluoric acid (1 ml). The solution was stirred overnight at room temperature then neutralised with aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica eluting with ethyl acetate to give the title compound (0.29 g) as a white solid.

Melting point: 135–137°C

MS (FAB) 437 ((M+H)⁺)

¹H NMR (CDCl₃) δ 1.78 (3H, s); 2.82 (2H, t); 3.42 (3H, s); 3.50-3.59 (2H, m); 3.79 (1H, t); 4.58 (2H, s); 4.81 (1H, s); 4.92 (1H, s); 6.02 (2H, s); 7.07 (1H, d); 7.40 (1H, t); 7.52-7.60 (2H, m); 7.83 (1H, d); 7.90 (1H, d); 8.24 (1H, d).

Example 4**3-(4-Hydroxybutyl)-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione****(a) 6-Chloro-3-methyl-1-(2-methylpropyl)pyrimidine-2,4[1H,3H]-dione**

3-Iodo-2-methylpropane (3.0 ml) and potassium carbonate (3.5 g) were added to a solution of 6-chloro-3-methylpyrimidine-2,4[1H,3H]-dione (Example 1(b), 4.02 g) in dimethylformamide (50 ml). The mixture was heated at 90°C for 24 hours then cooled to room temperature. The solution was diluted with hydrochloric acid (2.5 M) and extracted twice with diethyl ether. The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica eluting with iso-hexane : ethyl acetate (1:1) to give the subtitle compound (2.75 g) as a solid.

MS (ESI) 217/219 ((M+H)⁺).

¹H NMR (CDCl₃) δ 0.96 (6H, d); 2.10-2.22 (1H, m); 3.34 (3H, s); 3.90 (2H, d); 5.90 (1H, s).

(b) 6-Hydrazino-3-methyl-1-(2-methylpropyl)pyrimidine-2,4[1H,3H]-dione

Hydrazine hydrate (6.5 ml) was added to a solution of 6-chloro-3-methyl-1-(2-methylpropyl)pyrimidine-2,4[1H,3H]-dione (10.0 g) in ethanol (40 ml). The mixture was heated at reflux for 5 hours, cooled to room temperature and then evaporated under reduced pressure. The residue was recrystallised from ethanol to give the subtitle compound (8.8 g).

MS (APCI) 213 ((M+H)⁺).

¹H NMR (DMSO-d₆) δ 0.80 (6H, d); 1.92-2.07 (1H, m); 3.10 (3H, s); 3.70 (2H, d); 4.37 (2H, s, br); 5.11 (1H, s); 8.04 (1H, s, br).

(c) 1-Naphthaldehyde 3-methyl-1-(2-methylpropyl)-2,4[1H,3H]-dioxypyrimidine-6-hydrazone

6-Hydrazino-3-methyl-1-(2-methylpropyl)pyrimidine-2,4[1H,3H]-dione (2.5 g) was dissolved in warm methanol (100ml) and treated with 1-naphthaldehyde (1.7 ml). After 1 hour, the precipitated solid was filtered and recrystallised from toluene to give the subtitle compound (1.34 g).

MS (APCI) 351 ((M+H)⁺).


¹H NMR (DMSO-d₆) δ 0.90 (6H, d); 2.03-2.19 (1H, m); 3.17 (3H, s); 3.92 (2H, d); 5.78 (1H, s); 7.61 (2H, t); 7.70 (1H, t); 8.00 (1H, d); 8.04 (2H, d); 8.67 (1H, d); 9.07 (1H, s); 10.44 (1H, br s).

(d) 3-(4-Hydroxybutyl)-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione

5-Hydroxypentanal (0.65 ml) was added to a solution of 1-naphthaldehyde 3-methyl-1-(2-methylpropyl)-2,4[1H,3H]-dioxypyrimidine-6-hydrazone (250 mg) in dimethylformamide (5 ml). The solution was heated at reflux for 14 hours, cooled to room temperature and evaporated under reduced pressure. The residue was dissolved in ethyl acetate and washed twice with dilute hydrochloric acid, twice with saturated aqueous sodium bicarbonate solution, and then with brine. The organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica eluting with iso-hexane : ethyl acetate (1:1) and then ethyl acetate to give the title compound (116 mg) as a foam.

MS (APCI) 435 ((M+H)⁺)

¹H NMR (DMSO-d₆) δ 0.85 (6H, d); 1.32-1.48 (4H, m); 2.12-2.26 (1H, m); 2.93 (2H, t); 3.20-3.30 (5H, m); 3.73 (2H, d); 4.31 (1H, t); 5.91 (2H, s); 6.90 (1H, d); 7.43 (1H, t); 7.58-7.62 (2H, m); 7.89 (1H, d); 7.97-8.00 (1H, m); 8.22-8.30 (1H, m).

Example 5**5-Methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-propylthio-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione****(a) 5-Methyl-7-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione**

In accordance with the teaching of German Patent No. 63,381, phosphorus oxychloride (4 ml) was added dropwise to an ice cooled solution of 6-hydrazino-3-methyl-1-(2-methylpropyl)pyrimidine-2,4[1H,3H]-dione (4.7 g) in dimethylformamide (15 ml). After 1 hour the reaction mixture was quenched by pouring onto water. The precipitated solid was collected by filtration, and dried *in vacuo* to give the subtitle compound (3.4 g).

Melting point: 200°C

MS (-ve APCI) ((M-H)⁻) 221

¹H NMR (DMSO-d₆) δ 0.87 (6H, d), 2.22 (1H, m), 3.22 (3H, s), 3.77 (2H, d), 8.47 (1H, brs), 13.46 (1H, brs).

(b) 5-Methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione

In accordance with the teaching of German Patent No. 63,381, 1-(chloromethyl)-naphthalene (2.2 g), potassium carbonate (1.6 g) and 5-methyl-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione (2.5 g) were combined in acetone (40 ml) and heated under reflux for 3 hours and then cooled to ambient temperature. Water (200 ml) was added and the precipitated solid was collected by filtration. The solid was triturated with isohexane and then dried *in vacuo* to give the title compound (3.64 g).

Melting point: 178°C

MS (+ve APCI) ((M+H)⁺) 363

¹H NMR (DMSO-d₆) δ 0.83 (6H, d), 2.14 (1H, m), 3.19 (3H, s), 3.72 (2H, d), 5.88 (2H, s), 7.28 (1H, d), 7.48 (1H, t), 7.55-7.65 (2H, m), 7.93 (1H, d), 8.00 (1H, d), 8.22 (1H, d), 8.55 (1H, s).


5 (c) **5-Methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-propylthio-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione**

N-butyl lithium (1.5 M, 1.4 ml) was added to a solution of 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione (200 mg) and dipropyl disulfide (0.175 ml) in tetrahydrofuran (10 ml) cooled to -78°C. After 1 hour the
10 reaction mixture was warmed to ambient temperature and after a further hour the reaction was quenched with water. The reaction mixture was diluted with ether and washed thrice with 2 M sodium hydroxide solution and once with brine. The organic phase was dried over magnesium sulfate, concentrated *in vacuo* and purified by chromatography on silica gel (isohexane : ethyl acetate 9:1-4:1), followed by recrystallisation from isohexane to give
15 the title compound (24 mg).

Melting point: 105°C

MS (+ve APCI) ((M+H)⁺) 437

¹H NMR (DMSO d₆) δ 0.8-0.9 (9H, m), 1.4-1.5 (2H, m), 2.17 (1H, m), 3.16 (2H, t), 3.23 (3H, s), 3.72 (2H, d), 5.99 (2H, s), 6.89 (1H, d), 7.43 (1H, t), 7.55-7.65 (2H, m),
20 7.89 (1H, d), 7.98 (1H, d), 8.30 (1H, d).

Example 6**3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione**

5 Lithium diisopropylamide (3.3 mmol) was added to a solution of 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione (600 mg) and 3-{[dimethyl(1,1-dimethylethyl)silyl]oxy}propyl 4-methylphenylthiosulfonate (J.Med.Chem.1995, 38, 2557) (720 mg) in tetrahydrofuran (20 ml) cooled to -78°C. After 2 hours the reaction mixture was warmed to ambient temperature and after a
10 further hour quenched with water. The reaction mixture was diluted with ethyl acetate and was washed twice with dilute hydrochloric acid, twice with saturated sodium hydrogen carbonate solution, once with brine, and then dried over magnesium sulfate, filtered and concentrated. The residue was dissolved in tetrahydrofuran (20 ml) and
15 tetrabutylammonium fluoride (1 M in tetrahydrofuran, 2 ml) was added. After 18 hours the reaction mixture was quenched with saturated sodium hydrogen carbonate solution and extracted with ether. The ether extract was washed once with water and once with brine, then dried over magnesium sulfate, filtered and concentrated. Chromatography of the residue on silica gel (isohexane : ethyl acetate 1:1-1:2) followed by preparative reverse phase HPLC and recrystallisation from isohexane : ethyl acetate gave the title compound
20 (156 mg).


Melting point: 135°C

MS (+ve APCI) ((M+H)⁺) 453

¹H NMR (DMSO d₆) δ 0.83 (6H, d), 1.5-1.6 (2H, m), 2.19 (1H, m), 3.23 (3H, s; 2H, t), 3.32 (2H, q), 3.73 (2H, d), 4.48 (1H, t), 5.99 (2H, s), 6.89 (1H, d), 7.43 (1H, t),
25 7.55-7.65 (2H, m), 7.89 (1H, d), 7.98 (1H, dd), 8.30 (1H, dd).

Example 7

Methyl 4-[(4,5,6,7-tetrahydro-5-methyl-7-{2-methylpropyl}-2-{1-naphthalenylmethyl}-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)thio]butanoic acid



5 **(a) 4,4,4-Trimethoxybutyl *para*-toluenethiosulfonate**

A mixture of *para*-toluenethiosulfonic acid potassium salt (24 mmol), trimethyl 4-bromoorthobutyrate (22 mmol) and hexamethylphosphoramide (30 ml) was stirred at room temperature for 48 hours and then poured into 10:1 hexane/diethyl ether (500 ml). The mixture was shaken vigorously, then washed with water (2 x 200 ml) and then with
10 brine. The organic phase was dried over magnesium sulfate and evaporated to dryness *in vacuo* to give the subtitle ester as an oil (5.3 g).

¹H NMR (CDCl₃) δ 1.95(2H, m), 2.37(2H, t), 2.44(3H, s), 3.02(2H, t), 3.16(9H, s), 7.33(2H, d), 7.80(2H, d).

15 **(b) Methyl 4-[(4,5,6,7-tetrahydro-5-methyl-7-{2-methylpropyl}-2-{1-naphthalenylmethyl}-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)thio]butanoate**

Lithium diisopropylamide (2.8 mmol) was added to a solution of 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione (500 mg) in tetrahydrofuran (20 ml) cooled to -78°C. After 10 minutes 4,4,4-trimethoxybutyl *para*-toluenethiosulfonate (1.2 g) was added to the reaction. After 2 hours
20 the reaction mixture was warmed to ambient temperature and after a further hour quenched with dilute hydrochloric acid. The reaction mixture was diluted with ethyl acetate and washed twice with dilute hydrochloric acid, twice with saturated sodium hydrogen carbonate solution, once with brine and then dried over magnesium sulfate. The organic

phase was concentrated *in vacuo* and the residue was chromatographed on silica gel (isohexane : ethyl acetate 3:1-2:1) and then triturated with isohexane to give the title compound (340 mg).


Melting point: 100°C

5 MS (+ve APCI) 495 ((M+H)⁺)

¹H NMR (DMSO d₆) δ 0.84 (6H, d), 1.65 (2H, quint), 2.19 (1H, m), 2.28 (2H, t), 3.20-3.25 (5H, m), 3.52 (3H, s), 3.74 (2H, d), 5.99 (2H, s), 6.89 (1H, d), 7.43 (1H, t), 7.55-7.65 (2H, m), 7.89 (1H, d), 8.00 (1H, dd), 8.30 (1H, dd).

10 **Example 8**

4-[(4,5,6,7-tetrahydro-5-methyl-7-{2-methylpropyl}-2-{1-naphthalenylmethyl}-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)thio]butanoic acid



Lithium hydroxide monohydrate (80 mg) was added to a solution of methyl 4-[(4,5,6,7-tetrahydro-5-methyl-7-{2-methylpropyl}-2-{1-naphthalenylmethyl}-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)thio]butanoic acid (250 mg) in tetrahydrofuran (20 ml) and water was then added to give a homogeneous solution. After 18 hours the reaction mixture was partitioned between ether and 2 M sodium hydroxide. The aqueous phase was acidified with concentrated hydrochloric acid and extracted with ethyl acetate which was then dried over magnesium sulfate. The organic phase was concentrated *in vacuo* and recrystallised from cyclohexane : ethyl acetate to give the title compound (130 mg).


Melting point: 149°C

20 MS (+ve APCI) 481 ((M+H)⁺)

^1H NMR (DMSO d_6) δ 0.84 (6H, d), 1.65 (2H, quint), 2.10-2.25 (3H, m), 3.20-3.25 (5H, m), 3.74 (2H, d), 5.99 (2H, s), 6.90 (1H, d), 7.45 (1H, t), 7.55-7.65 (2H, m), 7.89 (1H, d), 7.98 (1H, dd), 8.29 (1H, dd).

5 **Example 9**

3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(2-phenylsulfonylmethyl)phenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione



10 **(a) 3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione**

Lithium diisopropylamide (10.7 mmol) was added to a solution of 2-(4-methoxyphenylmethyl)-5-methyl-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione (1.83 g) and 3-{[dimethyl(1,1-dimethylethyl)silyl]oxy}propyl 4-methylphenylthiosulfonate (J. Med. Chem. 1995, 38, 2557) (3.0 g) in tetrahydrofuran (30 ml) at -78°C. After 1.5 hours the reaction mixture was warmed to ambient temperature and after a further 2 hours water was added. The reaction mixture was diluted with ethyl acetate and washed twice with dilute hydrochloric acid, twice with saturated sodium hydrogen carbonate solution, once with brine and then dried over magnesium sulfate and concentrated *in vacuo*. The residue was dissolved in trifluoroacetic acid (10 ml) and heated to 100°C for 4 hours. The mixture was allowed to cool and was then evaporated under reduced pressure. The residue was dissolved in methanol (30 ml), saturated sodium hydrogen carbonate (1.1 g) was added, and the mixture was stirred at room temperature for 1 hour and then evaporated under reduced pressure. The resultant residue was dissolved in

15
20

ethyl acetate and washed once with saturated sodium hydrogen carbonate solution, twice with brine, then dried over magnesium sulfate and concentrated *in vacuo*. Chromatography on silica gel (isohexane : ethyl acetate 1:2) gave the title compound (1.0 g).

Melting point: 103-9°C

5 MS (+ve APCI) 313 ((M+H)⁺)

¹H NMR (DMSO d₆) δ 0.87 (6H, d), 1.70 (2H, vbrs), 2.20 (1H, vbrs), 3.18 (5H, s), 3.47 (2H, t), 3.70 (2H, d).

(b) 3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(2-
10 {phenylsulfonylmethyl}phenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-
dione




3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-1H-pyrazolo[3,4-d]-
pyrimidine-4,6(5H,7H)-dione (94 mg), potassium carbonate (90 mg) and
2-(phenylsulfonylmethyl)benzyl bromide (105 mg) were combined in dimethylsulfoxide
15 (11 ml). After 5 hours at room temperature the reaction mixture was diluted with ethyl
acetate and washed thrice with water, twice with dilute hydrochloric acid, once with brine,
then dried over magnesium sulfate and then concentrated *in vacuo*. Chromatography on
silica gel (isohexane : isopropanol 4:1) gave the title compound (70 mg).

Melting point: 50°C (foam)

20 MS (+ve APCI) 557 ((M+H)⁺)

¹H NMR (DMSO d₆) δ 0.81 (6H, d), 1.54 (2H, quint), 2.12 (1H, m), 3.19 (2H, t),
3.22 (3H, s), 3.37 (2H, q), 3.68 (2H, d), 4.48 (1H, t), 5.00 (2H, s), 5.61 (2H, s),
6.70 (1H, d), 7.13 (1H, d), 7.2-7.3 (2H, m), 7.65 (2H, t), 7.78 (1H, t), 7.82 (2H, d).

25 The following compounds were prepared following the method of Example 9(b) using
3-[(3-hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-
4,6(5H,7H)-dione and the appropriate halide.

Example	Name	Mfg. Pt.	MS	¹ H NMR
 10	2-[(5-Chlorobenzyl)(3-hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	144°C		(CDCl ₃) δ 0.93 (6H, d), 1.80 (2H, quint), 2.30 (1H, m), 2.60 (1H, brt), 3.30 (2H, t), 3.40 (3H, s), 3.80 (2H, brq), 3.85 (2H, d), 5.50 (2H, s), 6.00 (2H, s), 6.30 (1H, s), 6.90 (1H, s).
 11	2-(3-Chloro-2-fluorophenylthio)-3-[(3-hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	76-9°C	455/457	(CDCl ₃) δ 0.90 (6H, d), 1.84 (2H, quint), 2.22 (1H, m), 2.65 (1H, brt), 3.18 (2H, t), 3.40 (3H, s), 3.62 (2H, brq), 4.00 (2H, d), 5.55 (2H, s), 6.86 (1H, dt), 7.02 (1H, dt), 7.33 (1H, dt).
 12	3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(2-quinolinylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	131°C	454	(DMSO-d ₆) δ 0.83 (6H, d), 1.60 (2H, quint), 2.21 (1H, m), 3.20 (2H, t), 3.24 (3H, s), 3.30 (2H, q), 3.72 (2H, d), 4.54 (1H, t), 5.80 (2H, s), 7.28 (1H, d), 7.60 (1H, dt), 7.74 (1H, dt), 7.88 (1H, d), 8.00 (1H, d), 8.37 (1H, d).

Pharmacological data

Example 13


Inhibition of Human Mixed Lymphocyte Reaction (MLR)

5 The MLR test was performed in 96-well flat bottomed microtitre plates. Compounds were prepared as 10 mM stock solution in dimethyl sulphoxide. A 50 fold dilution of this was prepared in RPMI. Serial dilutions were prepared from this solution. 10 µl of the 50 fold
10 diluted stock, or dilutions of it, were added to the well to give concentrations in the assay starting at 9.5 µM and going down. Into each well was placed 1.5×10^5 cells from each of two responding donors in a final volume of 0.2 ml RPMI 1640 medium supplemented with 10% human serum, 2 mM L-glutamine and penicillin/streptomycin. The cells were incubated at 37 °C in a humidified atmosphere at 5% carbon dioxide for 120 hours. ^3H -Thymidine (0.5 µCi) was added for the final 6 hours of the incubation. The level of radioactivity incorporated by the cells was then determined, which is a measure of T-cell
15 proliferation.

The title compounds of Examples 1 to 12 were found to exhibit an IA_{50} value of less than 1×10^{-6} M in the above test.

CLAIMS

1. A compound of formula (I):



(I)

in which:

R^1 is C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} cycloalkyl;

10 R^2 is C_{1-4} alkyl or C_{3-6} alkenyl;

R^3 is 1- or 2-indanyl, 1- or 2-(1,2,3,4-tetrahydronaphthalenyl), 9-fluorenyl, acenaphthyl or $CHR^4(CH_2)_nAr$ where n is 0 or 1, R^4 is hydrogen or C_{1-6} alkyl and Ar is quinolinyl, naphthalenyl, benzodioxolinyl optionally substituted by one or more halogen atoms, or phenyl optionally substituted by one or more substituent groups selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy and phenylsulfonylmethyl;

15 C_{1-6} alkyl, C_{1-6} alkoxy and phenylsulfonylmethyl;

W is H, CH_2OH , CO_2H , $CO_2C_{1-6}alkyl$, $CH_2NR^5R^6$, $CONR^5R^6$, where R^5 and R^6 are independently hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocyclic ring optionally further containing an oxygen atom or a group NR^7 where R^7 is hydrogen or C_{1-6} alkyl, or W is pyridyl or phenyl, each of which may be optionally substituted by one or more substituent groups selected from halogen, hydroxyl, C_{1-6} alkyl and C_{1-6} alkoxy;

20 X is a bond or C_{1-5} alkylene;

Y is $S(O)_p$, $C\equiv C$, $CH=CH$, CH_2CH_2 or $CH_2CH=CH$; and

p is 0, 1 or 2;

25 or a pharmaceutically acceptable salt thereof, provided that:

- X is not a bond when W is H, CH₂OH, CO₂H, CO₂C₁₋₆alkyl, CH₂NR⁵R⁶ or CONR⁵R⁶ and Y is sulfur.

2. A compound according to claim 1, wherein R¹ is C₁₋₄alkyl or C₃₋₄alkenyl.

3. A compound according to claim 1 or claim 2, wherein R² is C₁₋₄alkyl.

4. A compound according to any one of claims 1 to 3, wherein R³ is CHR⁴(CH₂)_nAr in which n is 0, R⁴ is hydrogen and Ar is quinolinyl, naphthalenyl, benzodioxolinyl

substituted by one or more halogen atoms, or phenyl substituted by one or more substituent groups selected from halogen atoms and phenylsulfonylmethyl.

5. A compound according to any one of the preceding claims, wherein Y is sulfur or CH₂CH₂.

6. A compound according to any one of the preceding claims, wherein X is C₁₋₃alkylene.

7. A compound according to any one of the preceding claims, wherein W is H, CH₂OH, CO₂H, CO₂C₁₋₆alkyl or pyridyl.

8. A compound according to claim 1 which is:

3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione, or

5-Methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-3-[(2-pyridinyl)thio]-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione, or

3-[(2-Hydroxyethyl)thio]-5-methyl-7-(2-methyl-2-propenyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione, or

3-(4-Hydroxybutyl)-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6[5H,7H]-dione, or

5-Methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-propylthio-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, or

3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, or

5 Methyl 4-[(4,5,6,7-tetrahydro-5-methyl-7-{2-methylpropyl}-2-{1-naphthalenylmethyl}-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)thio]butanoic acid, or

4-[(4,5,6,7-tetrahydro-5-methyl-7-{2-methylpropyl}-2-{1-naphthalenylmethyl}-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl)thio]butanoic acid, or

10 3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(2-{phenylsulfonylmethyl}phenylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, or

2-({5-Chlorobenzo[1,3]dioxol-6-yl}methyl)-3-[(3-hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, or


2-(3-Chloro-2-fluorophenylmethyl)-3-[(3-hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, or

15 3-[(3-Hydroxypropyl)thio]-5-methyl-7-(2-methylpropyl)-2-(2-quinolinylnmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, or

a pharmaceutically acceptable salt of any one thereof.

9. A process for the preparation of a compound of formula (I) as defined in claim 1 which
20 comprises

(a) reaction of a compound of formula (II):




(II)

in which R^1 , R^2 and R^3 are as defined in formula (I) with a compound of formula (III):



- 5 in which L is a leaving group, Y is sulphur, and X and W are as defined in formula (I), or
 (b) when Y is CH_2CH_2 or $\text{CH}_2\text{CH}=\text{CH}$ and R^3 is $\text{CHR}^4(\text{CH}_2)_n\text{Ar}$, reaction of a compound of formula (IV):




10

(IV)


in which $R^{3'}$ is a precursor to the R^3 group $\text{CHR}^4(\text{CH}_2)_n\text{Ar}$ and R^1 and R^2 are as defined in formula (I), with a compound of formula (V):

15





in which Y is CH_2CH_2 or $\text{CH}_2\text{CH}=\text{CH}$ and W and X are as defined in formula (I), or
 (c) when Y is $\text{C}\equiv\text{C}$, $\text{CH}=\text{CH}$ or $\text{CH}_2\text{CH}=\text{CH}$, reacting a compound of formula (VI):

20



(VI)

in which L^1 represents a leaving group and R^1 , R^2 and R^3 are as defined in formula (I) with a compound of formula (VII) or (VIII):



wherein, in formula (VII), X^a is a bond or C_{1-6} alkylene and W is as defined in formula (I), and wherein, in formula (VIII), W and X are as defined in formula (I), and optionally thereafter:

- converting the compound of formula (I) to a further compound of formula (I), and/or
- forming a pharmaceutically acceptable salt.

10. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8 in combination with a pharmaceutically acceptable diluent or carrier.

11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 8 with a pharmaceutically acceptable diluent or carrier.

12. A compound of formula (I), or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 8 for use in therapy.

13. Use of a compound of formula (I), or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in therapy.

14. A method of effecting immunosuppression which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 8.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/00640

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 487/04, A61K 31/505, A61K 31/415 // (C07D 487/04, 239:00, 231:00)
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0063381 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 27 October 1982 (27.10.82) --	1-13
X	EP 0166054 A1 (TAKEDA CHEMICAL INDUSTRIES), 2 January 1986 (02.01.86) --	1-13
A	WO 9413643 A1 (PFIZER INC.), 23 June 1994 (23.06.94), page 13, line 11 - line 21; page 52, line 11 - page 53, line 18, the claims --	1-13
A	WO 9413677 A1 (PFIZER INC.), 23 June 1994 (23.06.94) --	1-13

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 June 1998

Date of mailing of the international search report

27 June 1998

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/00640

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4824848 A (TAKEHIKO NAKA ET AL), 25 April 1989 (25.04.89) --	1-13
A	J. Med. Chem., Volume 38, 1995, William F. Michne et al, "Novel Inhibitors of the Nuclear Factor of Activated T Cells (NFAT)-Mediated Transcription of beta-Galactosidase: Potential Immunosuppressive and Antiinflammatory Agents" page 2557 - page 2569 -- -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

09/06/98

International application No.

PCT/SE 98/00640

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
EP	0063381	A1	27/10/82	EP 0077372 A JP 58500966 T WO 8203626 A	27/04/83 09/06/83 28/10/82
EP	0166054	A1	02/01/86	SE 0166054 T3 CA 1263386 A DK 165409 B,C DK 584284 A IE 58160 B JP 1013712 B JP 1541656 C JP 61005082 A PT 79667 B US 4603203 A JP 60126285 A	28/11/89 23/11/92 15/06/85 28/07/93 07/03/89 31/01/90 10/01/86 10/12/86 29/07/86 05/07/85
WO	9413643	A1	23/06/94	AU 690527 B AU 5454894 A CA 2150483 A CN 1092768 A CZ 9501585 A EP 0674624 A FI 935674 A HU 67457 A HU 9303591 D IL 107946 D JP 7509725 T MX 9308042 A NO 952395 A NZ 257770 A PL 309356 A US 5712303 A ZA 9309404 A	30/04/98 04/07/94 23/06/94 28/09/94 17/01/96 04/10/95 18/06/94 28/04/95 00/00/00 00/00/00 26/10/95 31/08/94 16/08/95 24/02/97 02/10/95 27/01/98 15/06/95
WO	413677	A1	23/06/94	NONE	
US	4824848	A	25/04/89	DK 122587 A EP 0237289 A FI 871123 A PT 84478 B JP 63010788 A SU 1591811 A	15/09/87 16/09/87 15/09/87 10/11/89 18/01/88 07/09/90